Bin Liu, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Bin Liu, PhD

Professor, Department of Anesthesia, UCSF

liub@anesthesia.ucsf.edu

Phone: (415) 206-6973 (voice)
Box 1371, UCSF
San Francisco, CA 94110-1371

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics

Education

Princeton University, B.A., June 1990, Molecular Biology and Biochemical Sciences
University of California, San Francisco, Ph.D., Dec. 1994, Biochemistry and Biophysics


Professional Experience

  • 1995-1997
    Visiting fellow, Department of Dermatology, University of California school of medicine, San Francisco, California
  • 1998-2001
    Visiting fellow, Department of Anesthesia and Pharmaceutical chemistry, San Francisco General Hospital, San Francisco, California.
  • 2002-2006
    Assistant Professor, Department of Anesthesia, University of California, San Francisco.
  • 2006-2011
    Associate Professor, Department of Anesthesia, University of California, San Francisco.
  • 2011-present
    Professor, Department of Anesthesia, University of California, San Francisco.
  • 2003-present
    Program member, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.

Honors & Awards

  • 1990
    Summa Cum Laude (Princeton University)
  • 1990
    Phi Beta Kappa (Princeton University)
  • 1990
    Sigma Xi (Princeton University)
  • 1990
    Sigma Xi Book Award (Princeton University)
  • 1990
    E.R. Squibb and Sons Thesis Prize (Princeton University)
  • 1990
    George Khoury’65 Prize For Academic Excellence (Princeton University)
  • 1990,1991
    Regents’ Fellow (University of California at San Francisco)
  • 1994
    Chancellor's Fellow (University of California at San Francisco)
  • 1996-1999
    SmithKline Beecham Fellow of the Life Sciences Research Foundation
  • 1998
    Scleroderma Research Foundation investigator award
  • 2002
    American Cancer Society intramural research award
  • 2002
    BioSTAR/UC Discovery award
  • 2002
    CaPCure research award
  • 2002
    DOD New Investigator award
  • 2004
    MARF Investigator award
  • 2006
    MARF Investigator award
  • 2008
    AACR PanCan Pilot award
  • 2009
    UC Discovery SEED award
  • 2011
    MARF Investigator award

Selected Publications

  1. Combining Phage and Yeast Cell Surface Antibody Display to Identify Novel Cell Type-Selective Internalizing Human Monoclonal Antibodies. Methods Mol Biol. 2015; 1319:51-63.
    View on PubMed
  2. Utilizing Yeast Surface Human Proteome Display Libraries to Identify Small Molecule-Protein Interactions. Methods Mol Biol. 2015; 1319:203-14.
    View on PubMed
  3. Identification of Novel Protein-Ligand Interactions by Exon Microarray Analysis of Yeast Surface Displayed cDNA Library Selection Outputs. Methods Mol Biol. 2015; 1319:179-92.
    View on PubMed
  4. Identification of Posttranslational Modification-Dependent Protein Interactions Using Yeast Surface Displayed Human Proteome Libraries. Methods Mol Biol. 2015; 1319:193-202.
    View on PubMed
  5. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015 Mar; 29(2):81-91.
    View on PubMed
  6. High-content Analysis of Antibody Phage-display Library Selection Outputs Identifies Tumor Selective Macropinocytosis-dependent Rapidly Internalizing Antibodies. Mol Cell Proteomics. 2014 Dec; 13(12):3320-31.
    View on PubMed
  7. Methods for site-specific drug conjugation to antibodies. MAbs. 2014 Jan-Feb; 6(1):46-53.
    View on PubMed
  8. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. 2012; 2012:126906.
    View on PubMed
  9. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012 Jun; 14(3):336-47.
    View on PubMed
  10. Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomas. Cancer Res. 2011 Apr 1; 71(7):2428-32.
    View on PubMed
  11. The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. Biomaterials. 2011 Apr; 32(10):2605-13.
    View on PubMed
  12. Identification of protein/target molecule interactions using yeast surface-displayed cDNA libraries. Methods Mol Biol. 2011; 729:211-23.
    View on PubMed
  13. Construction of yeast surface-displayed cDNA libraries. Methods Mol Biol. 2011; 729:199-210.
    View on PubMed
  14. Comprehensive analysis of yeast surface displayed cDNA library selection outputs by exon microarray to identify novel protein-ligand interactions. Mol Cell Proteomics. 2011 Mar; 10(3):M110.005116.
    View on PubMed
  15. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 2010 Sep; 18(9):1650-6.
    View on PubMed
  16. Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Mol Cancer Ther. 2010 Jul; 9(7):2131-41.
    View on PubMed
  17. Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment. J Nucl Med. 2010 Mar; 51(3):427-32.
    View on PubMed
  18. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 2010 Jan 4; 141(1):13-21.
    View on PubMed
  19. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med (Berl). 2009 May; 87(5):507-14.
    View on PubMed
  20. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res. 2009 Feb 15; 69(4):1570-7.
    View on PubMed

Go to UCSF Profiles, powered by CTSI